Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM‐HF

Journal of the American Heart Association(2021)10.1161/jaha.120.019238Source: DataRank Database

Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM‐HF is a research paper published in Journal of the American Heart Association (2021). On theSindex it has a DataRank of 1.6. It has been cited 52 times, with 46 citing works in its 1-hop citation network.

N/A

1.6DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access52 citations · 46 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT01035255

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 5.12)OA: goldTopics (76)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 38%Citation Network 62%

Base Score Contribution

0.596

From this paper's citation signal

Citation Network Contribution

0.964

From 31 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 46 citers.

Pulmonary Hypertension Across the Spectrum of Left Heart and Lung Disease
European Journal of Heart Failure202413 citations28 referencesContributes 0.094
Outcomes and predictors of one-year mortality in patients hospitalized with Acute Heart Failure
IJC Heart & Vasculature202212 citations29 referencesContributes 0.088
Phenotyping Patients with Chronic Obstructive Pulmonary Disease and Heart Failure
ESC Heart Failure202414 citations31 referencesContributes 0.087
DIGitoxin to Improve Outcomes in Patients with Advanced Chronic Heart Failure (DIGIT-HF): Baseline Characteristics Compared to Recent Randomized Controlled Heart Failure Trials
European Journal of Heart Failure202512 citations31 referencesContributes 0.083
Real-life effectiveness of sacubitril/valsartan in older Belgians with heart failure, reduced ejection fraction and most severe symptoms
Scientific Reports20245 citations26 referencesContributes 0.069

Authors (17)

Leanne Mooney ORCID,Pooja Dewan ORCID,Akshay S. Desai ORCID,Ninian N. Lang ORCID,Martin Lefkowitz

Live enrichment

PubMed:33522249 PMC:PMC7955331 OpenAlex:https://openalex.org/W3129156895

British Heart Foundation

Grant: RE/18/6/34217

FWCI

5.12

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc

journalhttps://www.ahajournals.org/doi/pdf/10.1161/JAHA.120.019238

publisherhttps://www.ahajournals.org/doi/pdf/10.1161/JAHA.120.019238

publisherhttps://www.ahajournals.org/doi/full/10.1161/JAHA.120.019238

journalhttps://doi.org/10.1161/jaha.120.019238

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33522249

Fields of Study

Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsPulmonary Hypertension Research and TreatmentsAgedAminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiomarkersBiphenyl CompoundsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug CombinationsEnalaprilFemaleFollow-Up StudiesHeart FailureHospitalizationHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPrognosisProspective StudiesPulmonary Disease, Chronic ObstructiveStroke VolumeTime FactorsValsartanVentricular Function, Left

MeSH Terms

ValsartanAgedAminobutyratesAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug CombinationsEnalaprilFemaleFollow-Up StudiesHeart FailureHospitalizationHumansMaleMiddle AgedPeptide FragmentsPrognosisProspective StudiesStroke VolumeTime FactorsBiomarkersVentricular Function, LeftNatriuretic Peptide, BrainPulmonary Disease, Chronic ObstructiveAngiotensin Receptor Antagonists

Keywords

MedicineEjection fractionCOPDHeart failureInternal medicineCardiologyHazard ratioEnalaprilValsartanNatriuretic peptideHeart failure with preserved ejection fractionAngiotensin-converting enzymeConfidence intervalBlood pressureMortalityHospitalizationRight VentricleNeprilysinchronic obstructive pulmonary disease

Sustainable Development Goals

SDG 0: Good health and well-being